The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes

被引:17
|
作者
Scully, Kevin J. [1 ,5 ]
Palani, Gurunanthan [2 ]
Zheng, Hui [3 ]
Moheet, Amir [2 ]
Putman, Melissa S. [1 ,4 ]
机构
[1] Boston Childrens Hosp, Div Endocrinol, Boston, MA USA
[2] Univ Minnesota, Div Endocrinol Diabet & Metab, Minneapolis, MN USA
[3] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA USA
[4] Massachusetts Gen Hosp, Diabet Res Ctr, Boston, MA USA
[5] Boston Childrens Hosp, Div Endocrinol, 300 Longwood Ave, Boston, MA 02115 USA
关键词
Continuous glucose monitor; Control IQ; Hybrid closed loop system; Cystic fibrosis-related diabetes; CHILDREN; MANAGEMENT; PATIENT;
D O I
10.1089/dia.2021.0354
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cystic fibrosis-related diabetes (CFRD) is associated with pulmonary decline, compromised nutritional status, and earlier mortality. Although diabetes technology is increasingly being used in individuals with CFRD, there is a paucity of data investigating the impact of hybrid closed loop (HCL) technology on glycemia in this patient population.Materials and Methods: In this multicenter retrospective study of 13 adults and adolescents with CFRD, 14 days of continuous glucose monitor data were analyzed at baseline, 1 and 3 months after transition to the Tandem t:slim X2 pump with Control IQ (TM) technology, a HCL system.Results: Control IQ initiation was associated with a significant increase in % time in target range (70-180 mg/dL), as well as decreases in average glucose, % time in hyperglycemic ranges (% time >180 mg/dL, % time >250 mg/dL), and glycemic variability (standard deviation, coefficient of variation). There was no significant change in % time in hypoglycemia ranges (% time <54 mg/dL, % time <70 mg/dL).Conclusions: To our knowledge, this is the first study to report a beneficial effect of Food and Drug Administration (FDA)-approved HCL technology on glycemia in adults and adolescents with CFRD to date. Future studies are needed to understand the potential long-term glycemic benefits of HCL devices and to explore the impact of this technology on heath-related quality of life, pulmonary function, nutritional status, and mortality.
引用
收藏
页码:446 / 452
页数:7
相关论文
共 50 条
  • [1] PILOT STUDY OF CLOSED-LOOP GLYCEMIC CONTROL WITH THE BIONIC PANCREAS IN CYSTIC FIBROSIS-RELATED DIABETES
    Sherwood, J. S.
    Jafri, R.
    Sloane, J.
    Balliro, C.
    Putman, M. S.
    Russell, S. J.
    [J]. PEDIATRIC PULMONOLOGY, 2018, 53 : 405 - 406
  • [2] Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis-Related Diabetes
    Christian, Francis
    Thierman, Andrew
    Shirley, Erin
    Allen, Karen
    Cross, Cory
    Jones, Kellie
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS, 2019, 7
  • [3] The Unique Management of Cystic Fibrosis-Related Diabetes and the Importance of Glycemic Control
    Delaney, Rebecca A.
    Windemuth, Brenda
    [J]. JNP-JOURNAL FOR NURSE PRACTITIONERS, 2014, 10 (09): : 78 - 82
  • [4] Effect of Elexacaftor/Tezacaftorllvacaftor on Glycemic Control in Cystic Fibrosis-Related Diabetes Mellitus: A Chart Review
    Kravchenko, Maria
    Warren, Whittney
    [J]. DIABETES, 2021, 70
  • [5] Automated glycemic control with the bionic pancreas in cystic fibrosis-related diabetes: A pilot study
    Sherwood, Jordan S.
    Jafri, Rabab Z.
    Balliro, Courtney A.
    Zheng, Hui
    El-Khatib, Firas H.
    Damiano, Edward R.
    Russell, Steven J.
    Putman, Melissa S.
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2020, 19 (01) : 159 - 161
  • [6] Sputum Glucose and Glycemic Control in Cystic Fibrosis-Related Diabetes: A Cross-Sectional Study
    Van Sambeek, Lindsey
    Cowley, Elise S.
    Newman, Dianne K.
    Kato, Roberta
    [J]. PLOS ONE, 2015, 10 (03):
  • [7] Elexacaftor/Tezacaftor/Ivacaftor Improves Glycemic Control in Pediatric Patients with Cystic Fibrosis-Related Diabetes
    Shi, Melody
    Elmallah, Mai
    Benjamin, Robert
    [J]. HORMONE RESEARCH IN PAEDIATRICS, 2021, 94 (SUPPL 2): : 26 - 26
  • [8] Management of cystic fibrosis-related diabetes in children and adolescents
    O'Riordan, Stephen M. P.
    Robinson, Paul D.
    Donaghue, Kim C.
    Moran, Antoinette
    [J]. PEDIATRIC DIABETES, 2009, 10 : 43 - 50
  • [9] Glycemic control and FEV 1 recovery during pulmonary exacerbations in pediatric cystic fibrosis-related diabetes
    Okoniewski, William
    Hughan, Kara S.
    Weiner, Gabriel A.
    Weiner, Daniel J.
    Forno, Erick
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2020, 19 (03) : 460 - 465
  • [10] Management of cystic fibrosis-related diabetes in children and adolescents
    Moran, Antoinette
    Pillay, Kubendran
    Becker, Dorothy J.
    Acerini, Carlo L.
    [J]. PEDIATRIC DIABETES, 2014, 15 : 65 - 76